Welcome to our dedicated page for International Stem Cell SEC filings (Ticker: ISCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
international stem cell corporation (otcbb:isco) develops a powerful new stem cell technology called “parthenogenesis” that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection. parthenogenesis utilizes unfertilized human eggs to create “parthenogenetic” stem cells (hpsc) that can be “immune-matched” to millions of persons of differing sexes and racial backgrounds. a relatively small number of hpsc lines could provide sufficient immune-matched cells to cover large parts of the world’s population. isco plans to create a bank of these valuable hpsc lines (unistemcell™) to serve all populations across the world. human parthenogenetic stem cells have great therapeutic potential, yet do not require viable human embryos, thus avoiding ethical issues. isco’s scientists are focused on using hpsc to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven clinically yet is limiInternational Stem Cell Corporation reported the results of its annual stockholder meeting held on June 17, 2025. Stockholders elected four directors to serve until the 2026 annual meeting, including Andrey Semechkin and Russell Kern, each receiving 2,457,143 votes for with no votes withheld, and Donald A. Wright and Paul V. Maier, each receiving 7,772,429 votes for and 19,267 votes withheld. Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 7,715,844 votes for, 73,393 against, and 2,459 abstentions. In addition, stockholders advised that future votes on executive compensation should be held every three years, with 7,593,833 votes favoring a three-year frequency, compared with 142,581 for one year and 50,443 for two years.
International Stem Cell Corporation reported Q3 2025 results. Product sales were $2.369 million, up from $2.179 million a year ago, and income from operations was $94 thousand versus a prior loss. Net income was $57 thousand compared with a net loss of $125 thousand in Q3 2024.
Cash was $966 thousand at quarter-end, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional financing or extensions of existing financing. A related party note payable is presented at $3.305 million within current liabilities, and its maturity was extended to September 15, 2026.
Sales were led by the biomedical segment (LCT) with $2.204 million; the skin care segment (LSC) contributed $165 thousand. One customer accounted for 54% of consolidated product sales in the quarter and 62% of accounts receivable as of September 30, 2025. Basic and diluted EPS were $0.00, with 8,004,389 weighted-average shares.
FAQ
What is the current stock price of International Stem Cell (ISCO)?
What is the market cap of International Stem Cell (ISCO)?
